Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Treatment of Failing Blebs With Ranibizumab
This study is currently recruiting participants.
Verified by The New York Eye & Ear Infirmary, December 2007
Sponsors and Collaborators: The New York Eye & Ear Infirmary
Genentech
Information provided by: The New York Eye & Ear Infirmary
ClinicalTrials.gov Identifier: NCT00570726
  Purpose

This study was designed to evaluate the efficacy and safety in the use of Ranibizumab, an effective vascular endothelial growth factor (VGEF) inhibitor, in treating patients with a failing bleb, characterized by increased fibrosis and vascularization of the conjuctiva, following trabeculectomy. Six subjects from one site will be enrolled in this study.


Condition Intervention Phase
Glaucoma, Open-Angle
Failing Bleb Following Trabeculectomy
Drug: Ranibizumab (Lucentis)
Phase I

Genetics Home Reference related topics: early-onset glaucoma
MedlinePlus related topics: Glaucoma
Drug Information available for: Ranibizumab
U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment
Official Title: Effect of Needle Bleb Revision With Ranibizumab as a Primary Intervention in a Failing Bleb Following Trabeculectomy

Further study details as provided by The New York Eye & Ear Infirmary:

Estimated Enrollment: 6
Study Start Date: June 2007
  Eligibility

Ages Eligible for Study:   40 Years and older
Genders Eligible for Study:   Both
Criteria

Inclusion Criteria:

  • Ability to provide written informed consent and comply with study assessments for the full duration of the study
  • Age > 40 years
  • Patients with Open-angle Glaucoma who have had trabeculectomy
  • Patients determined to have failing bleb with presence of superficial bleb vascularity and IOP increase on 3 successive visits without topical medication
  • Patients whose intraocular pressure (IOP) is above goal IOP after suture lysis and digital compression have been attempted

Exclusion Criteria:

  • Pregnancy (positive pregnancy test) or lactation.
  • Premenopausal women not using adequate contraception. The following are considered effective means of contraception: surgical sterilization or use of oral contraceptives, barrier contraception with either a condom or diaphragm in conjunction with spermicidal gel, an IUD, or contraceptive hormone implant or patch.
  • Current infection or inflammation in either eye
  • Any abnormality preventing reliable applanation tonometry in either eye
  • Other non-glaucomatous disease affecting visual field, (pituitary lesions, demyelinating disease, congenital optic nerve anomaly, prior retinal and optic nerve vascular occlusive disease, retinal dystrophy and degeneration, diabetes and HIV and AIDS infection)
  • Strabismus, nystagmus, monocular patient
  • Prior enrollment in the study
  • Any other condition that the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated
  • Participation in another simultaneous medical investigation or trial
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00570726

Contacts
Contact: Jeffrey Liebmann, MD 212-477-7540 ext 330 JML18@earthlink.net
Contact: John M Purcell, BA 212-477-7540 ext 302 jpurcell@nyee.edu

Locations
United States, New York
Glaucoma Associates of New York Recruiting
New York, New York, United States, 10003
Contact: Elena Ilitchev, MD     212-477-7540 ext 332     Ilitcheve@gmail.com    
Principal Investigator: Jeffrey Liebmann, MD            
Sponsors and Collaborators
The New York Eye & Ear Infirmary
Genentech
Investigators
Principal Investigator: Jeffrey Liebmann, MD Glaucoma Associates of New York
  More Information

Study ID Numbers: 07.10
Study First Received: December 9, 2007
Last Updated: December 9, 2007
ClinicalTrials.gov Identifier: NCT00570726  
Health Authority: United States: Food and Drug Administration

Study placed in the following topic categories:
Glaucoma
Eye Diseases
Glaucoma, Open-Angle
Blister
Hypertension
Ocular Hypertension

ClinicalTrials.gov processed this record on January 13, 2009